Mitchel S. Berger, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Mitchel S. Berger, MD

Chair, Department of Neurological Surgery, and Director, Brain Tumor Research Center, UCSF
Berthold and Belle N. Guggenhime Professorship, UCSF

bergerm@neurosurg.ucsf.edu

Phone: (415) 353-3933 (academic); (415) 353-7500 (clinic)
Box 0112, UCSF
San Francisco, CA 94143-0112

View on UCSF Profiles

Cancer Center Membership

Program Member » Neurologic Oncology

Research Summary

Dr. Berger's main clinical interests are the treatment of brain tumors in adults and children and of epilepsy related to brain tumors. He has extensive expertise in intraoperative mapping of the brain to identify the sites of motor, sensory, and language function and thereby avoid their involvement or injury during surgery.

Dr. Berger is Director of the Neuro-Oncology Surgery Program. His current research interests involve identifying molecular markers in gliomas as correlates of tumor progression and prognosis. He also works in conjunction with Dr. Krys Bankiewicz to test small molecule inhibitors in brain tumors using convection enhanced delivery. Other collaborations include functional mapping localization of language pathways in the brain in conjunction with Dr. Robert Knight and the Cognitive Neuroscience Graduate Program at UC Berkeley. Dr. Berger is currently the Principal Investigator of UCSF's SPORE Brain Tumor Program. He is also the Principal Investigator of a Pediatric Brain Tumor Foundation Institute award to study the origins and treatment of pediatric brain tumors.

Education

Harvard University, Cambridge, MA, A.B., 1975, Social Psychology
University of Miami, Miami, FL, M.D., 1979, Medicine
University of California, San Francisco, CA (UCSF), Dept. of Neurological Surgery, Brain Tumor Research Center (BTRC) Research Fellow 1983 - 1984 Neurosurgery
UCSF, BTRC, Neuro-Oncology Service, Clinical Fellow, 7/85 - 12/85, Neurosurgery
Hospital for Sick Children, Toronto, Ontario, Canada, Pediatric Neurosurgery Fellow, 1/86 - 6/86, Neurosurgery


Professional Experience

  • 1980 - 1982
    Residency, Dept. of Neurological Surgery, University of California, San Francisco, CA (UCSF)
  • 1986 - 1992
    Asst. Professor, Dept. of Neurological Surgery, University of Washington, Seattle, WA
  • 1990 - 1992
    Assoc. Professor, Dept. of Neurological Surgery, University of Washington, Seattle, WA
  • 1995 - 1992
    American Cancer Society Prof. of Clinical Oncology, University of Washington, Seattle, WA
  • 1996 - 1992
    Professor, Dept. of Neurological Surgery, University of Washington, Seattle, WA
  • 1997 - present
    Professor and Chair, Dept. of Neurological Surgery, UCSF, San Francisco, CA
  • 1997 - present
    Director, Brain Tumor Research Center, Dept. of Neurological Surgery, UCSF

Honors & Awards

  • 1997-Present
    Joint Section on Tumors Advisory Council, American Association of Neurological Surgeons and Congress of Neurological Surgeons
  • 1997-1999
    Vice-President, Congress of Neurological Surgeons; President, Society for Neuro-Oncology
  • 2002-Present
    America’s Top Doctors, peer-nominated referral index from Castle Connolly
  • 2006
    Tumor Section, 2006 Ronald L. Bittner Lecturer; 2006 Farber Award Winner
  • 2007–Present
    Board of Directors of the American Association of Neurological Surgeons
  • 2007–Present
    Member of the American Board of Neurological Surgeons
  • 2010
    Vice-President, American Association of Neurological Surgeons
  • 2011
    President Elect, American Association of Neurological Surgeons
  • 2012
    President, American Association of Neurological Surgeons

Selected Publications

  1. Walsh KM, Codd V, Rice T, Nelson CP, Smirnov IV, McCoy LS, Hansen HM, Elhauge E, Ojha J, Francis SS, Madsen NR, Bracci PM, Pico AR, Molinaro AM, Tihan T, Berger MS, Chang SM, Prados MD, Jenkins RB, Wiemels JL, Telomere Group EC, Samani NJ, Wiencke JK, Wrensch MR. Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Oncotarget. 2015 Dec 4.
    View on PubMed
  2. Lerner RG, Grossauer S, Kadkhodaei B, Meyers I, Sidorov M, Koeck K, Hashizume R, Ozawa T, Phillips JJ, Berger MS, Nicolaides T, James CD, Petritsch CK. Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells. Cancer Res. 2015 Dec 15; 75(24):5355-66.
    View on PubMed
  3. Meng L, Berger MS, Gelb AW. The Potential Benefits of Awake Craniotomy for Brain Tumor Resection: An Anesthesiologist's Perspective. J Neurosurg Anesthesiol. 2015 Oct; 27(4):310-7.
    View on PubMed
  4. Hervey-Jumper SL, Berger MS. Technical nuances of awake brain tumor surgery and the role of maximum safe resection. J Neurosurg Sci. 2015 Dec; 59(4):351-60.
    View on PubMed
  5. Sughrue M, Kane A, Rutkowski MJ, Berger MS, McDermott MW. Meningiomas of the Anterior Clinoid Process: Is It Wise to Drill Out the Optic Canal? Cureus. 2015; 7(9):e321.
    View on PubMed
  6. Racine CA, Li J, Molinaro AM, Butowski N, Berger MS. Neurocognitive Function in Newly Diagnosed Low-grade Glioma Patients Undergoing Surgical Resection With Awake Mapping Techniques. Neurosurgery. 2015 Sep; 77(3):371-9.
    View on PubMed
  7. Han SJ, Rutledge WC, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. Neurosurgery. 2015 Aug; 77(2):248-53.
    View on PubMed
  8. Han SJ, Englot DJ, Birk H, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence. Neurosurgery. 2015 Aug; 62 Suppl 1:160-5.
    View on PubMed
  9. Barajas RF, Phillips JJ, Vandenberg SR, McDermott MW, Berger MS, Dillon WP, Cha S. Pro-angiogenic cellular and genomic expression patterns within glioblastoma influences dynamic susceptibility weighted perfusion MRI. Clin Radiol. 2015 Oct; 70(10):1087-95.
    View on PubMed
  10. Gardner RC, Hess CP, Brus-Ramer M, Possin KL, Cohn-Sheehy BI, Kramer JH, Berger MS, Yaffe K, Miller B, Rabinovici GD. Cavum Septum Pellucidum in Retired American Pro-Football Players. J Neurotrauma. 2016 Jan 1; 33(1):157-61.
    View on PubMed
  11. Wilson SM, Lam D, Babiak MC, Perry DW, Shih T, Hess CP, Berger MS, Chang EF. Transient aphasias after left hemisphere resective surgery. J Neurosurg. 2015 Sep; 123(3):581-93.
    View on PubMed
  12. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O'Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med. 2015 Jun 25; 372(26):2499-508.
    View on PubMed
  13. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015 Jun 25; 372(26):2481-98.
    View on PubMed
  14. Zarnett OJ, Sahgal A, Gosio J, Perry J, Berger MS, Chang S, Das S. Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis. JAMA Neurol. 2015 May 1; 72(5):589-96.
    View on PubMed
  15. Hervey-Jumper SL, Li J, Lau D, Molinaro AM, Perry DW, Meng L, Berger MS. Awake craniotomy to maximize glioma resection: methods and technical nuances over a 27-year period. J Neurosurg. 2015 Aug; 123(2):325-39.
    View on PubMed
  16. Hervey-Jumper SL, Berger MS. In reply: reoperation for recurrent high-grade glioma: does tumor genetics play a role? Neurosurgery. 2015 Apr; 76(4):E497.
    View on PubMed
  17. Randhawa P, Pastrana DV, Zeng G, Huang Y, Shapiro R, Sood P, Puttarajappa C, Berger M, Hariharan S, Buck CB. Commercially Available Immunoglobulins Contain Virus Neutralizing Antibodies Against All Major Genotypes of Polyomavirus BK. Am J Transplant. 2015 Apr; 15(4):1014-20.
    View on PubMed
  18. van Thuijl HF, Mazor T, Johnson BE, Fouse SD, Aihara K, Hong C, Malmström A, Hallbeck M, Heimans JJ, Kloezeman JJ, Stenmark-Askmalm M, Lamfers ML, Saito N, Aburatani H, Mukasa A, Berger MS, Söderkvist P, Taylor BS, Molinaro AM, Wesseling P, Reijneveld JC, Chang SM, Ylstra B, Costello JF. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathol. 2015 Apr; 129(4):597-607.
    View on PubMed
  19. Barajas RF, Pampaloni MH, Clarke JL, Seo Y, Savic D, Hawkins RA, Behr SC, Chang SM, Berger M, Dillon WP, Cha S. Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma. Case Rep Radiol. 2015; 2015:731361.
    View on PubMed
  20. Rolston JD, Englot DJ, Benet A, Li J, Cha S, Berger MS. Frontal operculum gliomas: language outcome following resection. J Neurosurg. 2015 Apr; 122(4):725-34.
    View on PubMed

Go to UCSF Profiles, powered by CTSI